E. A. Partridge

599 total citations
14 papers, 510 citations indexed

About

E. A. Partridge is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. A. Partridge has authored 14 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. A. Partridge's work include HER2/EGFR in Cancer Research (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Lung Cancer Treatments and Mutations (4 papers). E. A. Partridge is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Lung Cancer Treatments and Mutations (4 papers). E. A. Partridge collaborates with scholars based in United Kingdom, Netherlands and Canada. E. A. Partridge's co-authors include Michael G. Hutchison, D. McKillop, Helen Swaisland, Megumi Fusé, William G. Bendena, Stephen S. Tobe, Ronald J. Nachman, Ian Orchard, William J. Herron and Nick Bushby and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

E. A. Partridge

14 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. A. Partridge United Kingdom	8	212	212	168	95	61	14	510
Peter Lassota United States	9	456 2.2×	113 0.5×	48 0.3×	27 0.3×	9 0.1×	12	730
Marianne A. Grant United States	14	613 2.9×	56 0.3×	32 0.2×	47 0.5×	26 0.4×	26	971
E Kasafírek Czechia	13	195 0.9×	162 0.8×	35 0.2×	98 1.0×	10 0.2×	65	474
P. Mahajan United Kingdom	13	562 2.7×	103 0.5×	32 0.2×	26 0.3×	8 0.1×	26	775
Yeong Sang Kim United States	13	614 2.9×	179 0.8×	191 1.1×	8 0.1×	9 0.1×	17	863
N.D. Hammond United States	8	326 1.5×	87 0.4×	62 0.4×	24 0.3×	7 0.1×	13	712
Verena Paulitschke Austria	15	291 1.4×	126 0.6×	39 0.2×	61 0.6×	7 0.1×	29	539
Anette Wärnmark Sweden	9	448 2.1×	97 0.5×	34 0.2×	70 0.7×	6 0.1×	11	743
Victoria Izumi United States	13	432 2.0×	137 0.6×	47 0.3×	21 0.2×	7 0.1×	22	601
Ernesto Nola Italy	13	539 2.5×	126 0.6×	45 0.3×	12 0.1×	7 0.1×	18	893

Countries citing papers authored by E. A. Partridge

Since Specialization

Citations

This map shows the geographic impact of E. A. Partridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. A. Partridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. A. Partridge more than expected).

Fields of papers citing papers by E. A. Partridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. A. Partridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. A. Partridge. The network helps show where E. A. Partridge may publish in the future.

Co-authorship network of co-authors of E. A. Partridge

This figure shows the co-authorship network connecting the top 25 collaborators of E. A. Partridge. A scholar is included among the top collaborators of E. A. Partridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. A. Partridge. E. A. Partridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Pickup, Kathryn, Scott Martin, E. A. Partridge, et al.. (2016). Acute liver effects, disposition and metabolic fate of [14C]-fenclozic acid following oral administration to normal and bile-cannulated male C57BL/6J mice. Archives of Toxicology. 91(7). 2643–2653. 3 indexed citations

Sarda, Sunil, E. A. Partridge, Kathryn Pickup, Alan McCarthy, & Ian D. Wilson. (2013). HPLC–MS Profiling and Structural Identification of [14C]-Diclofenac Metabolites in Mouse Bile. Chromatographia. 77(3-4). 233–239. 4 indexed citations

Martín, Paul, et al.. (2011). Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects. Clinical Therapeutics. 34(1). 221–237. 67 indexed citations

Partridge, E. A., et al.. (2008). Disposition and metabolism of the colchicine derivative [¹⁴C]-ZD6126 in rat and dog. Xenobiotica. 38(4). 399–421. 3 indexed citations

Partridge, E. A., et al.. (2007). Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (¹⁴C-ZD6126) to tumour-bearing mice. Xenobiotica. 37(3). 328–340. 9 indexed citations

Logié, Armelle, et al.. (2005). Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model. Cancer Research. 65. 1409–1409. 2 indexed citations

McKillop, David, E. A. Partridge, John Kemp, et al.. (2005). Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics. 4(4). 641–649. 109 indexed citations

McKillop, D., Michael G. Hutchison, E. A. Partridge, et al.. (2004). Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica. 34(10). 917–934. 115 indexed citations

McKillop, D., et al.. (2004). Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica. 34(10). 901–915. 40 indexed citations

10.

Scurr, Michelle, Christina Brock, Anne O’Donnell, et al.. (2004). Assessment of metabolism, excretion and pharmacokinetics of a single dose of [¹⁴C]-ZD6126 in patients with solid malignant tumors. Journal of Clinical Oncology. 22(14_suppl). 3083–3083. 3 indexed citations

11.

Scurr, Michelle, Ian Judson, Christina Brock, et al.. (2004). Assessment of metabolism, excretion and pharmacokinetics of a single dose of [¹⁴C]-ZD6126 in patients with solid malignant tumors. Journal of Clinical Oncology. 22(14_suppl). 3083–3083. 7 indexed citations

12.

Lenz, Eva M., Ian D. Wilson, Brian Wright, et al.. (2002). A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil™ (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. Journal of Pharmaceutical and Biomedical Analysis. 28(1). 31–43. 37 indexed citations

13.

Partridge, E. A., et al.. (2000). The metabolism and excretion of [14C] 2- and 4-chlorobenzoic acids in the rat. Journal of Pharmaceutical and Biomedical Analysis. 22(6). 1023–1028. 2 indexed citations

14.

Fusé, Megumi, E. A. Partridge, Ronald J. Nachman, et al.. (1999). Effects of an allatostatin and a myosuppressin on midgut carbohydrate enzyme activity in the cockroach Diploptera punctata. Peptides. 20(11). 1285–1293. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact